Key Highlights

  • Polar Capital Global Healthcare Trust plc (LSE:PCGH) fell 4.02% on 8 October 2026.
  • US healthcare stocks were weaker ahead of Thursday's open after the pharmaceutical industry sued US health authorities over most-favoured-nation pricing.
  • The trust recently traded at a small premium to net asset value and has been issuing new shares to meet demand.
  • Gross gearing of about 8% amplifies moves in the underlying portfolio.
  • The trust's financial year ended on 30 September, with annual results due in the coming months.

PCGH Shares Track Healthcare Sell-Off

Shares in Polar Capital Global Healthcare Trust plc (LSE:PCGH) fell 4.02% on Thursday 8 October 2026. The closed-end fund invests in a global portfolio of healthcare companies, from large pharmaceutical groups to medical technology and biotechnology firms, and measures performance against the MSCI ACWI Healthcare index in sterling.

The trust is a constituent of the FTSE All-Share index. Its lead managers are James Douglas and Gareth Powell of Polar Capital.

Key Reasons Behind the 4.02% Decline

The main driver was weakness in US healthcare shares. Ahead of Thursday's Wall Street open, healthcare stocks fell even as energy and consumer staples held up. PhRMA, the main US pharmaceutical lobby group, launched a lawsuit against the Department of Health and Human Services and Secretary Robert F. Kennedy Jr. over most-favoured-nation drug pricing. The policy seeks to link US prices to the lowest paid in other developed nations. The legal fight signals a long period of uncertainty for drug company revenue.

Regulatory risk also rose. The US Department of Justice named breaches of the Federal Food, Drug, and Cosmetic Act as a priority in its white-collar enforcement drive. Large pharmaceutical holdings, which form a big part of global healthcare portfolios, are directly exposed to such policy shifts.

The premium unwound. PCGH had been trading at a small premium to its net asset value, around 1.2% in late September, and had been issuing new shares to meet demand. When sentiment turns, a premium can disappear quickly, causing the share price to fall faster than the portfolio. Gross gearing of about 8% also magnifies portfolio losses.

Higher rates were a further factor. Federal Reserve minutes pointed to another rate increase, and bond yields stayed near multi-year highs, weighing on growth-oriented healthcare names.

Why Investors Are Watching PCGH

Healthcare has been a recovering sector in 2026 after a tough 2025 dominated by US drug pricing and Tariff worries. PCGH shares delivered a one-year return of more than 30% to early September, and the trust has outperformed its benchmark. Eli Lilly, a leader in obesity drugs, has been among its largest holdings, giving investors exposure to one of the strongest themes in global healthcare.

The board introduced shareholder-friendly reforms in recent years, which helped move the shares from a discount to a premium. The ability to issue shares at a premium shows healthy demand, as investors seek a diversified route into global healthcare with active management.

The trust pays a modest dividend, with an interim of 1.2p per share paid in August, but its focus is on capital growth rather than income.

Key Dates and Catalysts

The trust's financial year ended on 30 September 2026, and annual results with a manager review are expected in the coming months. Investors will look for the managers' views on US policy, obesity drugs, medical devices and biotech mergers.

Other catalysts include the progress of the industry lawsuit, the US Interest Rate path and third-quarter Earnings from major drug makers later in October. Online investor discussion has focused on whether the recent premium to NAV is sustainable and whether Thursday's pullback offers a better entry point.

Outlook

The 4.02% fall in Polar Capital Global Healthcare Trust plc (LSE:PCGH) reflects sector-wide policy risk and a shift in sentiment rather than trust-specific problems. With a diversified portfolio and experienced managers, the trust remains a core healthcare holding for many UK investors, but short-term moves will continue to follow US policy headlines.